Le Lézard
Classified in: Health
Subjects: PDT, FDA

AnX Robotica Announces FDA Clearance for ProScantm: A Groundbreaking AI Assisted Reading Tool for Small Bowel Video Capsule Endoscopy


PLANO, Texas, Jan. 3, 2024 /PRNewswire/ -- AnX Robotica, a pioneering force in advanced gastrointestinal visualization technologies, is excited to announce the FDA clearance of NaviCam ProScantm. Through the rigorous De Novo Submission Process, the FDA has granted clearance for ProScan, making it the first AI Assisted Reading Tool designed to aid small bowel capsule endoscopy reviewers for adult patients in whom the capsule endoscopy images were obtained for suspected small bowel bleeding.

First AI Assisted Reading Tool for Small Bowel Video Capsule Endoscopy.

ProScan software, an artificial intelligent (AI) assisted reading tool, leverages cutting-edge technology to revolutionize the field of gastroenterology. AnX Robotics ProScan is a significant step forward in capsule endoscopy by enabling physicians with the latest technology to efficiently care for their patients. 

"As a clinician deeply immersed in the field of gastroenterology, I am thrilled to witness the FDA clearance of ProScan. This groundbreaking AI Assisted Reading Tool represents a pivotal advancement in small bowel capsule endoscopy, particularly for patients suspected of gastrointestinal bleeding", stated Dr. Cristiano Spada, Professor of Gastroenterology and Director on Endoscopy and Digestive Surgery at Gemelli Hospital.  "This clearance marks a significant leap forward in our pursuit of elevating patient care standards and signifies a new era in gastroenterological diagnostics."

AnX Robotica's ProScan software is a valuable tool that complements clinician expertise. Importantly, it is not designed to replace clinical decision-making of the physician, but serves as a support system, enabling healthcare professionals to make well-informed and efficient decisions with the support of AI-assisted readings.

"We are delighted to announce the FDA clearance of NaviCam ProScan, a transformative AI Assisted Reading Tool that addresses a critical need in the realm of small bowel capsule endoscopy," said Stu Wildhorn, Vice President of Marketing and Product Management at AnX Robotica. "ProScan's clearance underscores its potential to significantly enhance diagnostic workflows, allowing clinicians to make more informed decisions in a timely manner."

With the clearance of ProScan and the innovation of the NaviCam® Magnetically Controlled Capsule Endoscopy System, AnX Robotica is working to expand the NaviCam® platform for additional visualization aids and therapeutic applications. In addition to the NaviCam SB System, AnX Robotica markets the NaviCam® Colon System in Europe. The company also offers IntraMarX® 3D, radiopaque markers for colonic transit studies in the US.

NaviCam® is a registered trademark of AnX Robotica Corporation.

MKT-0063 CYSRSSv1

SOURCE AnX Robotica


These press releases may also interest you

at 10:30
Flourishing Foundations Recovery has launched a new outpatient detox center in San Antonio, TX, aiming to help individuals tackle drug and alcohol addiction without pausing their daily lives. The new substance abuse treatment center ensures easy...

at 08:30
Toitures Hogue's commitment to providing its employees with a structured, professional working environment that guarantees complete safety in the workplace, both on the job and on the job site, has just been awarded its renewed ISO 45001...

26 avr 2024
The report titled "Anti-Mullerian Hormone Test Market by Product (POC Testing, Self-check Kits), End-User (Commercial Labs, Research & development), Distribution, Use - Global Forecast 2024-2030" is now available on 360iResearch.com's offering,...

26 avr 2024
Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and...

26 avr 2024
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the...

26 avr 2024
Appili Therapeutics Inc. (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000...



News published on and distributed by: